Brexpiprazole switch tied to low risk of metabolic abnormalities, adverse events
For patients with schizophrenia, a switch to brexpiprazole appears to be safe, carrying low long-term risk of metabolic abnormalities, hyperprolactinemia, extrapyramidal symptoms, and QT interval (QTc) prolongation, with minimal changes in psychiatric symptoms, according to a study.
